 Merrimack Pharmaceuticals MACK the Company or Merrimack announced today it is rescheduling its 2019 Annual Meeting of Shareholders the 2019 Annual Meeting for October 17, 2019. The decision to postpone the meeting was made by Merrimacks Board of Directors based on ongoing recent discussions with significant shareholders and a desire to reach a constructive solution to avoid a potentially costly and distracting proxy contest with JFL Capital Management LLC, which has nominated four director candidates for the Companys Board. Preliminary proxy statement materials for the 2019 Annual Meeting are under review with the Securities and Exchange Commission SEC and have not yet been filed in definitive form nor been distributed to shareholders. 